Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Somatic recombination underlies frequent revertant mosaicism in loricrin keratoderma.

Suzuki S, Nomura T, Miyauchi T, Takeda M, Fujita Y, Nishie W, Akiyama M, Ishida-Yamamoto A, Shimizu H.

Life Sci Alliance. 2019 Feb 4;2(1). pii: e201800284. doi: 10.26508/lsa.201800284. Print 2019 Feb.

2.

Congenital nevi with hypomelanosis and fine scales.

Natsuga K, Oiso N, Kurokawa I, Tsubura A, Nakamura H, Maya Y, Nishie W, Kawada A, Shimizu H.

Eur J Dermatol. 2019 Jan 21. doi: 10.1684/ejd.2018.3496. [Epub ahead of print]

PMID:
30670370
3.

Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open-label, single-arm, phase 1/2 study on 10 Japanese patients.

Kurihara Y, Yamagami J, Funakoshi T, Ishii M, Miyamoto J, Fujio Y, Kakuta R, Tanikawa A, Aoyama Y, Iwatsuki K, Ishii N, Hashimoto T, Nishie W, Shimizu H, Kouyama K, Amagai M.

J Dermatol. 2019 Feb;46(2):124-130. doi: 10.1111/1346-8138.14732. Epub 2018 Dec 26.

PMID:
30585649
4.

Fc-binding proteins enhance autoantibody-induced BP180 depletion in pemphigoid.

Iwata H, Kamaguchi M, Ujiie H, Ujiie I, Natsuga K, Nishie W, Shimizu H.

J Pathol. 2019 Mar;247(3):371-380. doi: 10.1002/path.5196. Epub 2019 Jan 16.

PMID:
30426510
5.

BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid.

Tuusa J, Lindgren O, Tertsunen HM, Nishie W, Kokkonen N, Huilaja L, Izumi K, Herukka SK, Miettunen J, Shimizu H, Remes AM, Tasanen K.

J Invest Dermatol. 2019 Feb;139(2):293-299. doi: 10.1016/j.jid.2018.09.010. Epub 2018 Oct 10.

PMID:
30315782
6.

A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.

Schauer F, Kern JS, Virtic O, Technau-Hafsi K, Meiss F, Thoma K, Athanasiou I, Sitaru C, Di Zenzo G, Izumi K, Nishie W, Shimizu H, Bruckner-Tuderman L, Kiritsi D.

Br J Dermatol. 2019 Jan;180(1):231-232. doi: 10.1111/bjd.17146. Epub 2018 Nov 13. No abstract available.

PMID:
30188568
7.

The direct binding of collagen XVII and collagen IV is disrupted by pemphigoid autoantibodies.

Kamaguchi M, Iwata H, Nishie W, Toyonaga E, Ujiie H, Natsuga K, Kitagawa Y, Shimizu H.

Lab Invest. 2019 Jan;99(1):48-57. doi: 10.1038/s41374-018-0113-9. Epub 2018 Aug 8.

PMID:
30089857
8.

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading.

Takama H, Yoshida M, Izumi K, Yanagishita T, Muto J, Ohshima Y, Nishie W, Shimizu H, Akiyama M, Watanabe D.

Acta Derm Venereol. 2018 Nov 5;98(10):983-984. doi: 10.2340/00015555-3010. No abstract available.

9.

Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.

Kawaguchi Y, Shimauchi R, Nishibori N, Kawashima K, Oshitani S, Fujiya A, Shibata T, Ohashi N, Izumi K, Nishie W, Shimizu H, Arima H, Sobajima H.

J Diabetes Investig. 2019 Mar;10(2):392-398. doi: 10.1111/jdi.12877. Epub 2018 Jul 25.

10.

Doxycycline-Inducible Autoimmune Blistering Skin Disease Model.

Nishie W, Shimizu H.

In: Nakao K, Minato N, Uemoto S, editors. Innovative Medicine: Basic Research and Development [Internet]. Tokyo: Springer; 2015.

11.

Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.

Mai Y, Nishie W, Sato K, Hotta M, Izumi K, Ito K, Hosokawa K, Shimizu H.

Front Immunol. 2018 Apr 12;9:542. doi: 10.3389/fimmu.2018.00542. eCollection 2018.

12.

Regulatory T-cell dysfunction induces autoantibodies to bullous pemphigoid antigens in mice and human subjects.

Muramatsu K, Ujiie H, Kobayashi I, Nishie W, Izumi K, Ito T, Yoshimoto N, Natsuga K, Iwata H, Shimizu H.

J Allergy Clin Immunol. 2018 Dec;142(6):1818-1830.e6. doi: 10.1016/j.jaci.2018.03.014. Epub 2018 Apr 26.

PMID:
29704593
13.

Detection of anti-BP180 NC16A autoantibodies after the onset of dipeptidyl peptidase-IV inhibitor-associated bullous pemphigoid: a report of three patients.

Mai Y, Nishie W, Izumi K, Yoshimoto N, Morita Y, Watanabe M, Toyonaga E, Ujiie H, Iwata H, Fujita Y, Nomura T, Sato-Matsumura KC, Shimizu S, Shimizu H.

Br J Dermatol. 2018 Sep;179(3):790-791. doi: 10.1111/bjd.16656. Epub 2018 Jun 25. No abstract available.

PMID:
29624639
14.

Life before and beyond blistering: The role of collagen XVII in epidermal physiology.

Natsuga K, Watanabe M, Nishie W, Shimizu H.

Exp Dermatol. 2018 Mar 31. doi: 10.1111/exd.13550. [Epub ahead of print] Review.

PMID:
29604146
15.

Chromosomal inversions as a hidden disease-modifying factor for somatic recombination phenotypes.

Nomura T, Suzuki S, Miyauchi T, Takeda M, Shinkuma S, Fujita Y, Nishie W, Akiyama M, Shimizu H.

JCI Insight. 2018 Mar 22;3(6). pii: 97595. doi: 10.1172/jci.insight.97595.

16.

High Expression of Collagen XVII Compensates for its Depletion Induced by Pemphigoid IgG in the Oral Mucosa.

Kamaguchi M, Iwata H, Ujiie H, Natsuga K, Nishie W, Kitagawa Y, Shimizu H.

J Invest Dermatol. 2018 Aug;138(8):1707-1715. doi: 10.1016/j.jid.2018.03.002. Epub 2018 Mar 9.

PMID:
29530535
17.

Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.

Horikawa H, Kurihara Y, Funakoshi T, Umegaki-Arao N, Takahashi H, Kubo A, Tanikawa A, Kodani N, Minami Y, Meguro S, Itoh H, Izumi K, Nishie W, Shimizu H, Amagai M, Yamagami J.

Br J Dermatol. 2018 Jun;178(6):1462-1463. doi: 10.1111/bjd.16479. Epub 2018 Apr 16. No abstract available.

PMID:
29478242
18.

Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.

Maki N, Nishie W, Takazawa M, Kakurai M, Yamada T, Umemoto N, Kawase M, Izumi K, Shimizu H, Demitsu T.

J Dermatol. 2018 May;45(5):600-602. doi: 10.1111/1346-8138.14254. Epub 2018 Feb 14.

PMID:
29446164
19.

Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment.

Oya K, Fujii M, Taguchi S, Nishie W, Izumi K, Shimizu H.

Eur J Dermatol. 2018 Apr 1;28(2):250-251. doi: 10.1684/ejd.2018.3230. No abstract available.

PMID:
29400293
20.

Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models.

Sasaoka T, Ujiie H, Nishie W, Iwata H, Ishikawa M, Higashino H, Natsuga K, Shinkuma S, Shimizu H.

J Invest Dermatol. 2018 Jun;138(6):1260-1267. doi: 10.1016/j.jid.2018.01.005. Epub 2018 Jan 31.

PMID:
29391250
21.

Case of bullous pemphigoid associated with teneligliptin accompanied by severe mucous membrane involvement.

Kage Y, Yamaguchi Y, Uchida T, Izumi K, Nishie W, Shimizu H, Ishii N, Hashimoto T, Aihara M.

J Dermatol. 2018 Jul;45(7):e205-e206. doi: 10.1111/1346-8138.14237. Epub 2018 Jan 30. No abstract available.

PMID:
29380425
22.

Ramucirumab-induced Multiple Haemangiomas of the Skin: Two Case Reports.

Kosumi H, Nishie W, Sugai T, Toyonaga E, Yoshimoto N, Nakamura H, Horibe R, Kitamura Y, Nakatsumi H, Shimizu H.

Acta Derm Venereol. 2018 Apr 16;98(4):454-455. doi: 10.2340/00015555-2869. No abstract available.

23.

A possible association between BP230-type bullous pemphigoid and dementia: a report of two cases in elderly patients.

Zheng M, Ujiie H, Muramatsu K, Sato-Matsumura KC, Maeda T, Ujiie I, Iwata H, Izumi K, Nishie W, Shimizu H.

Br J Dermatol. 2018 Jun;178(6):1449-1450. doi: 10.1111/bjd.16249. Epub 2018 Apr 6. No abstract available.

PMID:
29278417
24.

HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors.

Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, Nakamura A, Nomoto H, Cho KY, Sato N, Nishimura M, Ito T, Izumi K, Nishie W, Shimizu H.

J Invest Dermatol. 2018 May;138(5):1201-1204. doi: 10.1016/j.jid.2017.11.023. Epub 2017 Dec 2. No abstract available.

PMID:
29203362
25.

A severe case of mango dermatitis.

Miyazawa H, Nishie W, Hata H, Matsumura K, Shimizu H.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e160-e161. doi: 10.1111/jdv.14656. Epub 2017 Nov 22. No abstract available.

PMID:
29080314
26.

Extensive Eruptive Syringoma After Liver Transplantation.

Maeda T, Natsuga K, Nishie W, Yamashita K, Shimizu H.

Acta Derm Venereol. 2018 Jan 12;98(1):119-120. doi: 10.2340/00015555-2814. No abstract available.

27.

Primary cutaneous diffuse large B-cell lymphoma presenting as a solitary subcutaneous nodule with TP53 and FBXW7 mutations.

Yoshimoto N, Yanagi T, Matsumura W, Ujiie I, Izumi K, Ando S, Nishie W, Fujii K, Nishihara H, Shimizu H.

Int J Dermatol. 2017 Dec;56(12):1459-1461. doi: 10.1111/ijd.13756. Epub 2017 Sep 27. No abstract available.

PMID:
28960258
28.

Loss of interaction between plectin and type XVII collagen results in epidermolysis bullosa simplex.

Natsuga K, Nishie W, Nishimura M, Shinkuma S, Watanabe M, Izumi K, Nakamura H, Hirako Y, Shimizu H.

Hum Mutat. 2017 Dec;38(12):1666-1670. doi: 10.1002/humu.23344. Epub 2017 Oct 6.

PMID:
28941359
29.

Oral mucosa is a useful substrate for detecting autoantibodies of mucous membrane pemphigoid.

Kamaguchi M, Iwata H, Ujiie H, Izumi K, Natsuga K, Nishie W, Asaka T, Kitagawa Y, Shimizu H.

Br J Dermatol. 2018 Feb;178(2):e119-e121. doi: 10.1111/bjd.15925. Epub 2018 Jan 15. No abstract available.

PMID:
28865101
30.

Case of bullous pemphigoid accompanied by collagenous gastroenteritis.

Shiba-Tokuchi K, Moriuchi R, Morita Y, Takashima Y, Shirato T, Koike Y, Izumi K, Nishie W, Shimizu S.

J Dermatol. 2017 Dec;44(12):e365-e366. doi: 10.1111/1346-8138.14028. Epub 2017 Sep 1. No abstract available.

PMID:
28862318
31.

C-Terminal Processing of Collagen XVII Induces Neoepitopes for Linear IgA Dermatosis Autoantibodies.

Toyonaga E, Nishie W, Izumi K, Natsuga K, Ujiie H, Iwata H, Yamagami J, Hirako Y, Sawamura D, Fujimoto W, Shimizu H.

J Invest Dermatol. 2017 Dec;137(12):2552-2559. doi: 10.1016/j.jid.2017.07.831. Epub 2017 Aug 24.

32.

In vitro and in vivo models to investigate the pathomechanisms and novel treatments for pemphigoid diseases.

Bieber K, Koga H, Nishie W.

Exp Dermatol. 2017 Dec;26(12):1163-1170. doi: 10.1111/exd.13415. Epub 2017 Nov 2. Review.

PMID:
28833569
33.

Disappearing subcutaneous papules and nodules: Characteristic features of muscle herniation and piezogenic pedal papules.

Mai Y, Nishie W, Sugai T, Imafuku K, Arita K, Shimizu H.

J Dermatol. 2017 Dec;44(12):e361-e362. doi: 10.1111/1346-8138.14005. Epub 2017 Aug 15. No abstract available.

PMID:
28815687
34.

Detection of mucous membrane pemphigoid autoantibodies by full-length BP180 enzyme-linked immunosorbent assay.

Izumi K, Nishie W, Mai Y, Ujiie H, Iwata H, Natsuga K, Shimizu H.

J Dermatol Sci. 2017 Nov;88(2):247-248. doi: 10.1016/j.jdermsci.2017.07.005. Epub 2017 Jul 13. No abstract available.

PMID:
28736219
35.

A case of idiopathic angioedema exacerbated by angiotensin receptor blocker administration.

Haga N, Nishie W, Morita Y, Mizuno O, Ohguchi Y, Shimizu H.

Int J Dermatol. 2017 Dec;56(12):1504-1505. doi: 10.1111/ijd.13675. Epub 2017 Jul 13. No abstract available.

PMID:
28703273
36.

Type XVII collagen coordinates proliferation in the interfollicular epidermis.

Watanabe M, Natsuga K, Nishie W, Kobayashi Y, Donati G, Suzuki S, Fujimura Y, Tsukiyama T, Ujiie H, Shinkuma S, Nakamura H, Murakami M, Ozaki M, Nagayama M, Watt FM, Shimizu H.

Elife. 2017 Jul 11;6. pii: e26635. doi: 10.7554/eLife.26635.

37.

Bullous pemphigoid following the replacement of vildagliptin with anagliptin.

Oya K, Fujii M, Taguchi S, Nishie W, Izumi K, Shimizu H.

J Dermatol. 2017 Oct;44(10):e238-e239. doi: 10.1111/1346-8138.13941. Epub 2017 Jul 7. No abstract available.

PMID:
28688147
38.

Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016.

Schmidt E, Spindler V, Eming R, Amagai M, Antonicelli F, Baines JF, Belheouane M, Bernard P, Borradori L, Caproni M, Di Zenzo G, Grando S, Harman K, Jonkman MF, Koga H, Ludwig RJ, Kowalczyk AP, Müller EJ, Nishie W, Pas H, Payne AS, Sadik CD, Seppänen A, Setterfield J, Shimizu H, Sinha AA, Sprecher E, Sticherling M, Ujiie H, Zillikens D, Hertl M, Waschke J.

J Invest Dermatol. 2017 Jun;137(6):1199-1203. doi: 10.1016/j.jid.2017.01.028. Epub 2017 Apr 5. Review.

39.

MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation.

Otsubo K, Goto H, Nishio M, Kawamura K, Yanagi S, Nishie W, Sasaki T, Maehama T, Nishina H, Mimori K, Nakano T, Shimizu H, Mak TW, Nakao K, Nakanishi Y, Suzuki A.

Oncogene. 2017 Jul 20;36(29):4201-4211. doi: 10.1038/onc.2017.58. Epub 2017 Mar 27.

PMID:
28346423
40.

Autoantibodies of non-inflammatory bullous pemphigoid hardly deplete type XVII collagen of keratinocytes.

Imafuku K, Iwata H, Kamaguchi M, Izumi K, Natsuga K, Ujiie H, Nishie W, Shimizu H.

Exp Dermatol. 2017 Dec;26(12):1171-1174. doi: 10.1111/exd.13331. Epub 2017 May 12.

PMID:
28266727
41.

Thymoma-associated multi-organ autoimmunity: two cases and a review of the literature.

Shiba K, Fujita Y, Miyazawa H, Muramatsu K, Watanabe M, Nishimura M, Shinkuma S, Nomura T, Nishie W, Taguchi J, Kinoshita I, Shimizu H.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):e324-e326. doi: 10.1111/jdv.14108. Epub 2017 Jan 23. No abstract available.

PMID:
28052464
42.

Two cases of erosive oral lichen planus with autoantibodies to desmoglein 3.

Muramatsu K, Nishie W, Natsuga K, Fujita Y, Iwata H, Yamada T, Yamashita E, Asaka T, Shimizu H.

J Dermatol. 2016 Nov;43(11):1350-1353. doi: 10.1111/1346-8138.13493. Epub 2016 Jul 26.

PMID:
27458049
43.

Macropinocytosis of type XVII collagen induced by bullous pemphigoid IgG is regulated via protein kinase C.

Iwata H, Kamaguchi M, Ujiie H, Nishimura M, Izumi K, Natsuga K, Shinkuma S, Nishie W, Shimizu H.

Lab Invest. 2016 Dec;96(12):1301-1310. doi: 10.1038/labinvest.2016.108. Epub 2016 Oct 24.

44.

Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid.

Izumi K, Nishie W, Mai Y, Wada M, Natsuga K, Ujiie H, Iwata H, Yamagami J, Shimizu H.

J Invest Dermatol. 2016 Nov;136(11):2201-2210. doi: 10.1016/j.jid.2016.06.622. Epub 2016 Jul 14.

45.

Bullous pemphigoid developed in a patient with prurigo nodularis.

Yoshimoto N, Ujiie H, Hirata Y, Izumi K, Nishie W, Shimizu H.

J Eur Acad Dermatol Venereol. 2017 Apr;31(4):e187-e189. doi: 10.1111/jdv.13911. Epub 2016 Aug 26. No abstract available.

PMID:
27511319
46.

Lichenoid drug eruption caused by clonazepam.

Muramatsu K, Ujiie H, Natsuga K, Nishie W, Shimizu H.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e117-e118. doi: 10.1111/jdv.13862. Epub 2016 Aug 9. No abstract available.

PMID:
27504530
47.

Plasma cell cheilitis successfully treated with topical calcineurin inhibitors.

Yamaguchi Y, Nishie W, Ito T, Shimizu H.

Eur J Dermatol. 2016 Dec 1;26(6):609-610. doi: 10.1684/ejd.2016.2858. No abstract available.

PMID:
27502182
48.

Early severe pachyonychia congenita subtype PC-K6a with a novel mutation in the KRT6A gene.

Cammarata-Scalisi F, Natsuga K, Toyonaga E, Nishie W, Shimizu H, Avendaño A, Araque D, Da Silva G, Bellacchio E, Callea M.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e94-e96. doi: 10.1111/jdv.13800. Epub 2016 Jul 21. No abstract available.

PMID:
27445120
49.

Subepidermal autoimmune bullous disease affecting predominantly mucocutaneous junctions and the palms with autoantibodies to BP230 and laminin γ1.

Honda Y, Dainichi T, Nishie W, Ujiie H, Hattori Y, Miyachi Y, Kabashima K.

Br J Dermatol. 2016 Sep;175(3):619-21. doi: 10.1111/bjd.14542. Epub 2016 Jun 6. No abstract available.

PMID:
26972908
50.

Epitope-Dependent Pathogenicity of Antibodies Targeting a Major Bullous Pemphigoid Autoantigen Collagen XVII/BP180.

Wada M, Nishie W, Ujiie H, Izumi K, Iwata H, Natsuga K, Nakamura H, Kitagawa Y, Shimizu H.

J Invest Dermatol. 2016 May;136(5):938-946. doi: 10.1016/j.jid.2015.11.030. Epub 2016 Jan 28.

Supplemental Content

Loading ...
Support Center